"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
Christina Farr, Luba Greenwood, Ash Zenooz
39 episodes
4 months ago
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.Â
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
All content for "Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD is the property of Christina Farr, Luba Greenwood, Ash Zenooz and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.Â
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co
Why is the longevity sector taking off? With Lifeforce CEO Dugal Bain-Kim
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
44 minutes
5 months ago
Why is the longevity sector taking off? With Lifeforce CEO Dugal Bain-Kim
In this episode of Second Opinion, Christina Farr and Lifeforce CEO Dugal Bain-Kim dive into the billion-dollar longevity economy, examining why health optimization became a status symbol and how personal data drives better health decisions than population-level advice.
—
đź“° Be notified early when Turpentine drops new publication: https://www.turpentine.co/exclusiveaccessÂ
—LINKS: Lifeforce: https://www.mylifeforce.com/Â
Christina Farr's Second Opinion Newsletter: https://secondopinion.media/Â
—FOLLOW:https://www.linkedin.com/in/dugal-bain https://www.linkedin.com/in/christinafarr/Â
—HIGHLIGHTS FROM THE EPISODE:• The "shadow healthcare system" refers to cash-pay healthcare alternatives where insured people seek services outside traditional insurance coverage.• This trend results from converging factors: post-COVID cultural shifts, health becoming aspirational/lifestyle status, and new technology enabling accessible longevity services.• Personalized data from wearables (like Aura rings showing sleep/alcohol impact) motivates behavior change more effectively than general medical advice.• "N of one" personalized data feels more relevant than population health guidance, though there's risk of "measuring the fun out of life."• Personal genetic risk (like Alzheimer's predisposition) transforms health behaviors from optional to urgent, particularly around sleep quality.• A paradox exists where physicians publicly skeptical of longevity medicine privately use interventions like GLP-1 microdosing and seek optimization partners.• Personal health testing reveals significant issues traditional healthcare misses, including PCOS, scoliosis, and device malfunctions.• Longevity medicine catches problems early - 26% of members are pre-diabetic, often undiagnosed despite regular annual physicals.• Continuous monitoring can discover serious conditions like pituitary brain tumors when primary care doctors aren't interested in investigating elevated biomarkers.• The equity challenge questions how expensive cash-pay services can reach populations who need them most.• Three customer types emerge: health optimizers, health-motivated people getting back on track, and people wanting complete health reinvention.• Solutions for broader access include insurance integration and AI-powered tools to reduce costs from $140 to $40 monthly.• The "dating app problem" asks whether longevity companies lose customers when they successfully improve health.• Solutions include maintenance vs. optimization modes, targeting 40-60 age demographic where significant bodily changes occur.• Despite male-focused industry branding, actual customer bases can be gender-balanced (45% female, 55% male).• Effective messaging balances performance-focused and wellness-focused approaches rather than targeting one gender.• Longevity medicine includes traditional prevention but adds quality-of-life interventions that create initial motivation and trust for broader health compliance.• The rebranding question asks whether longevity is simply primordial prevention made more engaging and actionable.• Supplement safety concerns arise from liver injuries and poor industry regulation, highlighting need for data-driven approaches.• Most people take too many unnecessary supplements; data-driven supplementation could improve both safety and efficacy.
"Second Opinion" with Christina Farr, Ash Zenooz MD & Luba Greenwood JD
If you’re obsessed with health-tech and life sciences, this is the podcast for you. Second Opinion doesn't hold back. Join Luba Greenwood, Christina Farr, and Ash Zenooz as they bring influential entrepreneurs, experts and investors into the ring for candid conversations at the frontlines of healthcare and digital health every week. Healthcare, health-tech and life sciences in particular, is hard to navigate even for the most seasoned professionals. Unpacking the latest technological, medical, and scientific advances, regulatory hurdles, global economic shifts, and industry and investment trends, requires a powerful combination of hosts like us.
We aim to sift through the noise and help you navigate what’s really going on in healthcare and how to spot the next win. This season, we’re tackling meaty topics like biosecurity, the latest in telemedicine, why patient acquisition is so hard, and the pros and cons of VC versus private equity in funding startups in the healthtech space.
Christina Farr is a former investigative journalist for CNBC — during her tenure as a reporter, she broke some big health-tech stories ranging from Amazon’s first moves into the sector to Apple’s secretive acquisitions. Now Christina is the author at Second Opinion, a newsletter with +20K subscribers. Joining Christina are co-hosts Luba Greenwood, JD — former CEO of Kojin Therapeutics and managing partner at Dana-Farber Cancer Institute — and Ash Zenooz, MD — former CEO of Commure and partner at Luxeda Holdings.Â
Second Opinion is is a part of the Turpentine podcast network. Learn more: turpentine.co